Positive early access decision by French Haute Autorité de Santé to use Idefirix as desensitization treatment for highly sensitized kidney transplant patients – Hansa Biopharma AB

Hansa Biopharma AB, the pioneer in enzyme technology for rare immunological conditions, announced that its first-in-class treatment Idefirix (imlifidase) has been granted early access post marketing authorization (Autorisation d’accès précoce) in France by French HAS (Haute Autorité de Santé) for use in the desensitization of highly sensitized adult patients prior to kidney transplant, in accordance with the patient population specified […]